American Journal of Obstetrics & Gynecology
Volume 199, Issue 5 , Pages 539.e1-539.e6 , November 2008

Influence of race on tolerance of platinum-based chemotherapy and clinical outcomes in women with advanced and recurrent cervical cancer: a pooled analysis of 3 Gynecologic Oncology Group studies

  • Steven C. Plaxe, MD

      Affiliations

    • Division of Gynecologic Oncology, University of California, San Diego, San Diego, CA
    • ,
  • Sandra E. Brooks, MD

      Affiliations

    • Division of Cancer Prevention and Gynecologic Oncology, Norton Cancer Institute Louisville, KY
    • ,
  • Chunquiao Tian, MS

      Affiliations

    • Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY
    • Corresponding Author InformationReprints: Ms Denise Mackey, GOG, Administrative Office, Four Penn Center, 1600 JKF Blvd, Suite 1020, Philadelphia, PA 19102
    • ,
  • Jeffrey D. Bloss, MD

      Affiliations

    • Genetech, Inc, South San Francisco, CA
    • ,
  • David H. Moore, MD

      Affiliations

    • Gynecologic Oncology of Indiana, Indianapolis, IN
    • ,
  • Harry J. Long, MD

      Affiliations

    • Department of Medical Oncology, Mayo Clinic, Rochester, MN

Received 21 September 2007 ,Revised 28 January 2008 ,Accepted 17 April 2008.

References 

  1. Thigpen T, Shingleton H, Homesley H, Lagasse L, Blessing J. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group. Cancer. 1981;48:899–903
  2. Muderspach LI, Blessing JA Levenback C, Moore JL. A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2001;81:213–215
  3. McGuire WP, Blessing JA, Moore D, Lentz S, Photopulos G. Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol. 1996;14:792–795
  4. Long HJ, Bundy BN, Grendys EC, Benda J, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2005;23:1–8
  5. Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, et al. Randomized trial of Cisplatin and Ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2002;20:1832–1837
  6. Moore DH, Blessing JA, McQuellan RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22:3113–3119
  7. Blackstock AW, Herndon JE, Paskett ED, Perry MC, Graziano SL, Muscato JJ, et al. Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Natl Cancer Inst. 2002;94:284–290
  8. Corbie-Smith G, Thomas SB, St. George MM. Distrust, race and research. Arch Intern Med. 2002;162:2458–2463
  9. Wendler D, Kington R, Madans J, Van Wye G, Christ-Schmidt H, Pratt LA, et al. Are racial and ethnic minorities less willing to participate in health research?. PLoS Med. 2006;3:201–210
  10. Brooks SE, Chen TT, Ghosh A, Mullins CD, Gardner JF, Baquet CR. Cervical cancer outcomes analysis: impact of age, race, and comorbid illness on hospitalizations for invasive carcinoma of the cervix. Gynecol Oncol. 2000;79:107–115
  11. McCollum AD, Catalao PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, et al. Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst. 2002;94:1160–1167
  12. Hershman D, Weinberg M, Rosner Z, Alexis K, Tierstein A, Grann V, et al. Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer. J Natl Cancer Inst. 2003;95:1545–1548
  13. Hershman D, McBride R, Jacobson J, Lamerato L, Roberts K, Grann V, et al. Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol. 2005;23:6639–6646
  14. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol. 1997;15:1544–1552
  15. Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D. Comorbidity and survival disparities among black and white patients with breast cancer. JAMA. 2005;294:1765–1772
  16. Brawley OW, Freeman HP. Race and outcomes: is this the end of the beginning for minority health research?. J Natl Cancer Inst. 1999;22:1908–1909
  17. Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA. Meta-analysis of survival in African American and White American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol. 2005;24:1342–1349

 This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group Administrative Office (CA 27469) and the Gynecologic Oncology Group Statistical and Data Center (CA 37517).

 Cite this article as: Plaxe SC, Brooks SE, Tian C, et al. Influence of race on tolerance of platinum-based chemotherapy and clinical outcomes in women with advanced and recurrent cervical cancer: a pooled analysis of 3 Gynecologic Oncology Group studies. Am J Obstet Gynecol 2008;199:539.e1-539.e6.

PII: S0002-9378(08)00434-1

doi: 10.1016/j.ajog.2008.04.038

American Journal of Obstetrics & Gynecology
Volume 199, Issue 5 , Pages 539.e1-539.e6 , November 2008

Article Tools

* Image Usage & Resolution